GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Plandai Biotechnology Inc (OTCPK:PLPL) » Definitions » Net Income

Plandai Biotechnology (Plandai Biotechnology) Net Income : $-19.80 Mil (TTM As of Jun. 2023)


View and export this data going back to . Start your Free Trial

What is Plandai Biotechnology Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. Plandai Biotechnology's Net Income for the six months ended in Jun. 2023 was $-19.80 Mil. Its Net Income for the trailing twelve months (TTM) ended in Jun. 2023 was $-19.80 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. Plandai Biotechnology's Earnings per Share (Diluted) for the six months ended in Jun. 2023 was $-0.00.


Plandai Biotechnology Net Income Historical Data

The historical data trend for Plandai Biotechnology's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Plandai Biotechnology Net Income Chart

Plandai Biotechnology Annual Data
Trend Mar09 Mar10 Mar11 Jun12 Jun13 Jun14 Jun15 Jun16 Jun22 Jun23
Net Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -15.61 -9.58 -4.38 6.82 -19.80

Plandai Biotechnology Semi-Annual Data
Mar03 Mar04 Mar05 Mar06 Mar07 Mar08 Mar09 Mar10 Mar11 Jun12 Jun13 Jun14 Jun15 Jun16 Jun22 Jun23
Net Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -15.61 -9.58 -4.38 6.82 -19.80

Plandai Biotechnology Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

Plandai Biotechnology's Net Income for the fiscal year that ended in Jun. 2023 is calculated as

Net Income(A: Jun. 2023 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-19.801+0+0+0
=-19.80

Plandai Biotechnology's Net Income for the quarter that ended in Jun. 2023 is calculated as

Net Income(Q: Jun. 2023 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-19.801+0+0+0
=-19.80

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Net Income for the trailing twelve months (TTM) ended in Jun. 2023 was $-19.80 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Plandai Biotechnology  (OTCPK:PLPL) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

Plandai Biotechnology's Earnings per Share (Diluted) (EPS) for the quarter that ended in Jun. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Plandai Biotechnology Net Income Related Terms

Thank you for viewing the detailed overview of Plandai Biotechnology's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Plandai Biotechnology (Plandai Biotechnology) Business Description

Traded in Other Exchanges
N/A
Address
4811 49th Street, San Diego, CA, USA, 92115
Plandai Biotechnology Inc. manufactures highly bioavailable extracts from live plant materials.
Executives
Callum Baylis-duffield director FLAT 37 ISLAND HOUSE THREE MILL LANE, LONDON ENGLAND X0 E33AF
Timothy Matula other: Former Director 175 JACKSON AVE N, SUITE 102, MINNEAPOLIS MN 55343
Brian Johnson director P.O. BOX 1594, FERNDALE WA 98248-1594
Roger Duffield director, officer: President, Secretary and CFO 2226 EASTLAKE AVENUE EAST #156, SEATTLE WA 98102
Daron Baylis Duffield director 2226 EASTLAKE AVENUE EAST #156, SEATTLE WA 98102
David Rzepnicki director 21 HORIZON DRIVE, SARATOGA SPRINGS NY 12866